Immune globulin intravenous (ADMA Biologics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameImmune globulin intravenous (ADMA Biologics)
Drug Alias NameRespiratory syncytial virus immune globulin - ADMA BiologicsImmune globulin intravenous humanIGIV-ADMA BiologicsAscenivRI-001 +[6] 
ClassificationBiologics > Blood componentsBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunostimulantsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsLower Respiratory Tract InfectionsImmunologic Deficiency SyndromesPrimary Immunodeficiency Diseases +[4] 
Global Approved IndicationsImmunologic Deficiency Syndromes
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/04/01
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineAdma Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAdma Biologics Inc
Active IndicationsImmunologic Deficiency Syndromes
Inactive IndicationsLower Respiratory Tract InfectionsPrimary Immunodeficiency DiseasesRespiratory Tract Infections

Other Information

ATC CodeJ06BA02
Related LinksN/A